JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Harmony Biosciences Holdings Inc

Fechado

SetorSaúde

35.13 -0.93

Visão Geral

Variação de preço das ações

24h

Atual

Mín

33.5

Máximo

35.32

Indicadores-chave

By Trading Economics

Rendimento

-3.9M

46M

Vendas

-17M

185M

P/E

Médio do Setor

13.114

34.393

Margem de lucro

24.663

Funcionários

268

EBITDA

-10M

56M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+38.94% upside

Dividendos

By Dow Jones

Próximos Ganhos

28 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

301M

2B

Abertura anterior

36.06

Fecho anterior

35.13

Sentimento de Notícias

By Acuity

34%

66%

108 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2025, 23:11 UTC

Ganhos

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 de ago. de 2025, 22:45 UTC

Ganhos

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 de ago. de 2025, 22:39 UTC

Ganhos

Great-West Lifeco Logs Lower 2Q Profit

5 de ago. de 2025, 21:32 UTC

Ganhos

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 de ago. de 2025, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 de ago. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 de ago. de 2025, 23:19 UTC

Conversa de Mercado

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 de ago. de 2025, 23:03 UTC

Conversa de Mercado
Ganhos

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 de ago. de 2025, 22:22 UTC

Ganhos

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 de ago. de 2025, 22:21 UTC

Ganhos

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 de ago. de 2025, 22:20 UTC

Ganhos

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 de ago. de 2025, 22:18 UTC

Ganhos

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 de ago. de 2025, 22:17 UTC

Ganhos

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 de ago. de 2025, 22:17 UTC

Ganhos

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 de ago. de 2025, 22:16 UTC

Ganhos

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 de ago. de 2025, 22:16 UTC

Ganhos

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 de ago. de 2025, 22:15 UTC

Ganhos

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 de ago. de 2025, 22:13 UTC

Ganhos

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 de ago. de 2025, 22:13 UTC

Ganhos

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 de ago. de 2025, 22:12 UTC

Ganhos

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 de ago. de 2025, 22:12 UTC

Ganhos

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 de ago. de 2025, 21:58 UTC

Ganhos

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 de ago. de 2025, 21:30 UTC

Ganhos

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 de ago. de 2025, 21:26 UTC

Ganhos

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 de ago. de 2025, 21:23 UTC

Ganhos

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 de ago. de 2025, 21:17 UTC

Ganhos

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Comparação entre Pares

Variação de preço

Harmony Biosciences Holdings Inc Previsão

Preço-alvo

By TipRanks

38.94% parte superior

Previsão para 12 meses

Média 49.38 USD  38.94%

Máximo 70 USD

Mínimo 31 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Harmony Biosciences Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

6

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

29.8 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Very Strong Bearish Evidence

Sentimento

By Acuity

108 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.